OncoStem Diagnostics named ‘Best Innovation- Cancer Risk Assessment’ by NASSCOM
Startups were selected based on their innovation quotient and impact
OncoStem Diagnostics, an Oncology focused company that enables personalised cancer treatment was named as ‘Best Innovation- Cancer Risk Assessment’ by NASSCOM’s CoE’s (Centre of Excellence) Life Sciences and healthcare innovation forum(LHIF).
NASSCOM invited applications from eligible startups working in healthcare to apply for the #LHIF Startup Awards 2019. A jury consisting of industry stalwarts and healthcare professionals selected six high-impact and tech-driven healthcare startups breaking new ground in the fields of Healthcare, Lifesciences, Medical Devices, Pharma and Insurance. Startups were selected based on their innovation quotient and impact. OncoStem’s test CanAssist Breast was awarded the “Best Innovation- Cancer Risk Assessment”.
CanAssist Breast is a prognostic test for early-stage hormone receptor-positive breast cancer patients. It makes customised treatment possible by analysing the patient's tumor in-depth and providing a patient-specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either ‘low or high’ with no grey area in between. This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated side-effects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.
Speaking about the award, Dr Manjiri Bakre, CEO and founder, OncoStem Diagnostics said “We are extremely happy to receive this award and to be recognised by an eminent body like NASSCOM. At OncoStem, our vision is to develop innovative tests that aid personalised cancer therapy and improve a patient’s quality of life. This recognition strengthens our commitment towards providing personalised treatments that are suited to a patient’s condition”